Data Sheet (Cat.No.T75135)

TargetMol

FHD-609

Chemical Properties



CAS No. : 2676211-64-4

Formula: C47H56N8O6

Molecular Weight: 829

Storage: Keep away from direct sunlight
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	FHD-609 is an effective BRD9 inhibitor and PROTAC degrader, targeting the non-classical BAF (ncBAF) subunit BRD9, thereby depleting the SS18-SSX fusion protein, and can be used for the study of synovial sarcoma (SS).
Targets(IC50)	Epigenetic Reader Domain,PROTACs
In vivo	In the SYO-1 xenograft mouse model, FHD-609 (1 mg/kg, intravenous injection, twice weekly for 28 days) maintained BRD9 degradation levels for 28 days and exhibited antitumor activity [3].

Solubility Information

Solubility	DMSO: 80 mg/mL (96.5 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.2063 mL	6.0314 mL	12.0627 mL
5 mM	0.2413 mL	1.2063 mL	2.4125 mL
10 mM	0.1206 mL	0.6031 mL	1.2063 mL
50 mM	0.0241 mL	0.1206 mL	0.2413 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Hescheler DA, et al. Targeted Therapy for Adrenocortical Carcinoma: A Genomic-Based Search for Available and Emerging Options. Cancers (Basel). 2022 May 31;14(11):2721.

Lin M, et al. Long acting injectable FHD-609 micro-suspension: A potent BRD9 degrader with comparable efficacy, reduced frequency of dosing in preclinical models[J]. Cancer Research, 2024, 84(6_Supplement): 7185-7185.

Collins M, et al. Preclinical validation of target engagement assays and investigation of mechanistic impacts of FHD-609, a clinical-stage BRD9 degrader being developed for the treatment of synovial sarcoma[J]. strategies, 2022, 36: 936-950.

Tel:781-999-4286 E_mail:info@targetmol.com Address:34 Washington Street,Wellesley Hills,MA 02481